Skip to main content

The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer

Abstract

Patients with estrogen receptor (ER)-positive breast cancer generally do not have significant response to neoadjuvant chemotherapy. In these patients, neoadjuvant endocrine therapy (NET) is an alternative for those who may benefit from tumor downsizing prior to surgery. This article reviews clinical trials that have defined the role of NET. Cumulatively, these trials demonstrate that NET is effective in downsizing ER-positive breast tumors. Aromatase inhibitors are preferred in postmenopausal patients. An aromatase inhibitor with ovarian suppression is effective in premenopausal patients. While trials to date have shown the effectiveness of NET to facilitate breast conservation, they have provided little data regarding optimal axillary management.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95(4):681–695.

    PubMed  Google Scholar 

  2. 2.

    Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–618.

    PubMed  Google Scholar 

  4. 4.

    Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258–264.

    PubMed  Google Scholar 

  5. 5.

    Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.

    PubMed  Google Scholar 

  6. 6.

    Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049–1060.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159.

    CAS  PubMed  Google Scholar 

  8. 8.

    von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.

    Google Scholar 

  9. 9.

    von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804.

    Google Scholar 

  10. 10.

    Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2019;26(11):3502–3509.

    PubMed  Google Scholar 

  11. 11.

    Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006(1):Cd004272.

  12. 12.

    Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17(2):460–469.

    CAS  PubMed  Google Scholar 

  13. 13.

    Swisher SK, Vila J, Tucker SL, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–756.

    PubMed  Google Scholar 

  14. 14.

    Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23(11):3467–3474.

    PubMed  PubMed Central  Google Scholar 

  15. 15.

    Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–121.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Cardoso F, Veer LJ, Bogaerts J et al. (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 375(8):717–729.

    CAS  PubMed  Google Scholar 

  17. 17.

    Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110(2):244–254.

    CAS  PubMed  Google Scholar 

  18. 18.

    Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001;12(11):1527–1532.

    CAS  PubMed  Google Scholar 

  19. 19.

    Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23(22):5108–5116.

    CAS  PubMed  Google Scholar 

  20. 20.

    WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization. https://apps.who.int/iris/handle/10665/37200. Published 1979. Accessed December 27, 2019.

  21. 21.

    Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106(10):2095–2103.

    CAS  PubMed  Google Scholar 

  22. 22.

    Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol. 2011;29(17):2342–2349.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23(12):3069–3074.

    CAS  PubMed  Google Scholar 

  24. 24.

    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216.

  25. 25.

    Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012;13(4):345–352.

    CAS  PubMed  Google Scholar 

  26. 26.

    Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–168.

    CAS  PubMed  Google Scholar 

  27. 27.

    Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481.

    CAS  PubMed  Google Scholar 

  28. 28.

    Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846.

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19(10):2596–2606.

    CAS  PubMed  Google Scholar 

  30. 30.

    Dixon JM, Love CD, Bellamy CO, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat. 2001;66(3):191–199.

    CAS  PubMed  Google Scholar 

  31. 31.

    Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000;18(22):3758–3767.

    CAS  Google Scholar 

  32. 32.

    Milla-Santos A, Milla L, Calvo N, et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res. 2004;24(2c):1315–1318.

    CAS  PubMed  Google Scholar 

  33. 33.

    Anderson TJ, Dixon JM, Stuart M, Sahmoud T, Miller WR. Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer. 2002;87(3):334–338.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2 Pt 2):951s–958s.

    CAS  PubMed  Google Scholar 

  35. 35.

    Leung SCY, Nielsen TO, Zabaglo LA, et al. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019;75(2):225–235.

    PubMed  Google Scholar 

  36. 36.

    Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists. J Clin Oncol. 2005;23(11):2477–2492.

    CAS  PubMed  Google Scholar 

  37. 37.

    Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99(2):167–170.

    CAS  PubMed  Google Scholar 

  38. 38.

    Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100(19):1380–1388.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Ellis MJ, Suman VJ, Hoog J, et al. Ki67 Proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: Results from the American College of Surgeons Oncology Group Z1031 trial (Alliance). J Clin Oncol. 2017;35(10):1061–1069.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Suman VJ, Ellis MJ, Ma CX. The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER +/Her2- invasive breast cancer. Chin Clin Oncol. 2015;4(3):34.

    PubMed  PubMed Central  Google Scholar 

  41. 41.

    Chiba A, Hoskin TL, Heins CN, Hunt KK, Habermann EB, Boughey JC. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: A National Cancer Data Base study. Ann Surg Oncol. 2017;24(2):418–424.

    PubMed  Google Scholar 

  42. 42.

    Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.

    CAS  PubMed  Google Scholar 

  43. 43.

    Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–8423.

    CAS  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–5685.

    CAS  PubMed  Google Scholar 

  45. 45.

    Allevi G, Strina C, Andreis D, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer. 2013;108(8):1587–1592.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123–133.

    CAS  PubMed  Google Scholar 

  47. 47.

    Ueno T, Saji S, Masuda N, et al. Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open. 2019;4(1):e000476.

    PubMed  PubMed Central  Google Scholar 

  48. 48.

    Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2020;21(2):250–260.

    CAS  PubMed  Google Scholar 

  49. 49.

    Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS). https://clinicaltrials.gov/ct2/show/NCT02764541. Accessed February 1, 2020.

  50. 50.

    A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with estrogen-receptor positive primary breast cancer (PALLET). https://clinicaltrials.gov/ct2/show/NCT02296801. Accessed April 6, 2020.

  51. 51.

    A neoadjuvant study of abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive, HER2 Negative Breast Cancer (neoMONARCH). https://clinicaltrials.gov/ct2/show/NCT02441946. Accessed April 6, 2020.

  52. 52.

    Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–575.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

T.A.K. has received speaker fees from Genomic Health. E.A.M. reports receiving honoraria from Physician Education Resource; paid compensation for participation on Scientific Advisory Boards for Genomic Health, Merck, Paregrine Pharmaceuticals, Sella Life Science, and Tapimmune; and research funding from Glaxo SmithKline. Her institution has received research funding from Astra Zeneca, EMD Serono, Galena Biopharma, and Genentech/Roche.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Elizabeth A. Mittendorf MD, PhD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Weiss, A., King, T.A. & Mittendorf, E.A. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. Ann Surg Oncol 27, 3393–3401 (2020). https://doi.org/10.1245/s10434-020-08530-6

Download citation